Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A retrospective study of NENs and miR-224 promotes apoptosis of BON-1 cells by targeting PCSK9 inhibition
Jian’an Bai, Na He, Xiumei Hua, et al.
Oncotarget (2016) Vol. 8, Iss. 4, pp. 6929-6939
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside
Xuhui Bao, Yongjun Liang, Hanman Chang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 59
PCSK9 and cancer: Rethinking the link
Khadijeh Mahboobnia, Matteo Pirro, Ettore Marini, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 140, pp. 111758-111758
Open Access | Times Cited: 75
PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma
Shi-Zhe Zhang, Xiao‐Dong Zhu, Long-Hai Feng, et al.
Experimental Hematology and Oncology (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 58
Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer
A. Bhattacharya, Abhirup Chowdhury, Koel Chaudhury, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2021) Vol. 1876, Iss. 1, pp. 188581-188581
Closed Access | Times Cited: 45
The evolving landscape of PCSK9 inhibition in cancer
Palak P. Oza, Khosrow Kashfi
European Journal of Pharmacology (2023) Vol. 949, pp. 175721-175721
Open Access | Times Cited: 22
MEG3 Suppresses Human Pancreatic Neuroendocrine Tumor Cells Growth and Metastasis by Down-Regulation of Mir-183
Yuanyuan Zhang, Haomiao Feng
Cellular Physiology and Biochemistry (2017) Vol. 44, Iss. 1, pp. 345-356
Open Access | Times Cited: 54
Post-transcriptional Regulation of PCSK9 by miR-191, miR-222, and miR-224
Parisa Naeli, Fatemeh Mirzadeh Azad, Mahshid Malakootian, et al.
Frontiers in Genetics (2017) Vol. 8
Open Access | Times Cited: 53
A rare rarity: Neuroendocrine tumor of the esophagus
Elisa Giannetta, Valentina Guarnotta, Francesca Silvia Rota, et al.
Critical Reviews in Oncology/Hematology (2019) Vol. 137, pp. 92-107
Closed Access | Times Cited: 46
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
Roberta Modica, Anna La Salvia, Alessia Liccardi, et al.
Endocrine (2024) Vol. 85, Iss. 2, pp. 520-531
Open Access | Times Cited: 6
MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?
Amir Abbas Momtazi, Maciej Banach, Matteo Pirro, et al.
Clinical Reviews in Allergy & Immunology (2017) Vol. 54, Iss. 2, pp. 224-233
Open Access | Times Cited: 37
Deep sequencing reveals distinct microRNA-mRNA signatures that differentiate pancreatic neuroendocrine tumor from non-diseased pancreas tissue
N. Matyašovská, Natália Valková, Manish Gala, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
The ever-expanding saga of the proprotein convertases and their roles in body homeostasis: emphasis on novel proprotein convertase subtilisin kexin number 9 functions and regulation
Nabil G. Seidah, Michel Chrètien, Majambu Mbikay
Current Opinion in Lipidology (2018) Vol. 29, Iss. 2, pp. 144-150
Closed Access | Times Cited: 31
miR‑224‑5p protects dental pulp stem cells from apoptosis by targeting Rac1
Wenlan Qiao, Dong Li, Qing Shi, et al.
Experimental and Therapeutic Medicine (2019)
Open Access | Times Cited: 28
LDL Receptor Pathway Regulation by miR-224 and miR-520d
Alessandro G. Salerno, Coen van Solingen, Elena Scotti, et al.
Frontiers in Cardiovascular Medicine (2020) Vol. 7
Open Access | Times Cited: 26
Coming Back to Physiology: Extra Hepatic Functions of Proprotein Convertase Subtilisin/Kexin Type 9
Klaus‐Dieter Schlüter, Annemarie Wolf, Rolf Schreckenberg
Frontiers in Physiology (2020) Vol. 11
Open Access | Times Cited: 21
MiRNA Expression in Neuroendocrine Neoplasms of Frequent Localizations
А. А. Коротаева, Danzan Mansorunov, Н. В. Апанович, et al.
Non-Coding RNA (2021) Vol. 7, Iss. 3, pp. 38-38
Open Access | Times Cited: 17
Association of PCSK9 Variants With the Risk of Atherosclerotic Cardiovascular Disease and Variable Responses to PCSK9 Inhibitor Therapy
Chayakrit Krittanawong, Muzamil Khawaja, Robert S. Rosenson, et al.
Current Problems in Cardiology (2021) Vol. 47, Iss. 7, pp. 101043-101043
Closed Access | Times Cited: 17
Current and New Challenges in the Management of Pancreatic Neuroendocrine Tumors: The Role of miRNA-Based Approaches as New Reliable Biomarkers
Andrei Havași, Daniel Sur, Simona Căinap, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1109-1109
Open Access | Times Cited: 12
Epigenetic Regulation in Gastroenteropancreatic Neuroendocrine Tumors
Judy S. Crabtree
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 12
The Link between miRNAs and PCKS9 in Atherosclerosis
Mirjana Mačvanin, Zoran Gluvić, Aleksandra Klisić, et al.
Current Medicinal Chemistry (2023) Vol. 31, Iss. 42, pp. 6926-6956
Closed Access | Times Cited: 7
Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
Huimin Sun, Wen Meng, Jie Zhu, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2022) Vol. 395, Iss. 6, pp. 643-658
Closed Access | Times Cited: 10
The uprise of RNA biology in neuroendocrine neoplasms: altered splicing and RNA species unveil translational opportunities
Ricardo Blázquez‐Encinas, María Trinidad Moreno-Montilla, Víctor García-Vioque, et al.
Reviews in Endocrine and Metabolic Disorders (2022) Vol. 24, Iss. 2, pp. 267-282
Open Access | Times Cited: 8
The Anti-Thrombotic Effects of PCSK9 Inhibitors
Martin Jozef Péč, J Benko, Jakub Jurica, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 9, pp. 1197-1197
Open Access | Times Cited: 4
The association between non-HDL cholesterol and high-grade pancreatic neuroendocrine neoplasms
Hao Zhou, Yong Zhu, Bin Qin, et al.
Endocrine (2024)
Closed Access | Times Cited: 1
The low-density lipoprotein receptor: emerging post-transcriptional regulatory mechanisms
Klevis Ndoj, Amber Meurs, Dimitra Papaioannou, et al.
Atherosclerosis (2024) Vol. 401, pp. 119082-119082
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top